Translational and Clinical Research (TACR)

项目总结/摘要（翻译和临床研究） 转化和临床研究（TACR）计划促进了实验室之间的沿着- 密歇根大学（U-）的预防-临床研究连续体和实体瘤疾病研究中心 M）Rogel癌症中心（Rogel）。TACR是Rogel的一个重要桥梁机制，将其 实验室和人口科学为基础的研究计划，产生创新的概念，代理， TACR转化为实体瘤患者导向研究的方法。TACR计划包括 79名成员来自15个不同的部门和四个不同的学校和学院。2022年，TACR计划 成员每年直接癌症相关资金总额为2080万美元，其中750万美元（36%）来自NCI; 该计划共有1020万美元（49%）的同行评审资金。此外，TACR成员拥有1060万美元 来自非同行和行业赞助商的赠款。会员共有出版物1457种，其中30.1%为 34.8%是方案内合作，34.8%是方案间合作。TACR计划有三个具体的 目的：1）开发和应用最先进的分子靶向方法来诊断和治疗癌症; 2)开发和测试跨肿瘤类型的新的预测生物标志物和疾病监测策略;以及3） 从Rogel癌症中心的科学计划到有影响力的临床试验，都有先进的概念。

PROJECT SUMMARY/ABSTRACT (TRANSLATIONAL AND CLINICAL RESEARCH) The Translational and Clinical Research (TACR) Program catalyzes collaborations along the laboratory- translational-clinical research continuum and across solid tumor disease sites in the University of Michigan (U- M) Rogel Cancer Center (Rogel). TACR represents a crucial bridging mechanism for the Rogel, linking its laboratory and population science based-research programs that generate innovative concepts, agents, and approaches that TACR translates to solid tumor patient-oriented research. The TACR Program is comprised of 79 members from 15 different departments and four different schools and colleges. In 2022, TACR Program members had a total of $20.8M in annual direct cancer-relevant funding, of which $7.5M (36%) was from NCI; the Program had a total of $10.2M (49%) in peer-reviewed funding. In addition, TACR members had $10.6 million in grants from non-peer and industry sponsors. Members have a total of 1457 publications, of which 30.1% are intra-programmatic and 34.8% are inter-programmatic collaborations. The TACR program has three Specific Aims: 1) Develop and apply state-of-the-art molecularly targeted approaches to cancer diagnosis and treatment; 2) Develop and test new predictive biomarker and disease-monitoring strategies across tumor types; and 3) Advance concepts emanating from Rogel Cancer Center scientific programs to impactful clinical trials.